Posted by Michael Wonder on 26 Jul 2016
CADTH recommends reimbursement of Sunvepra
20 July 2016 - CADTH has recommended that asunaprevir (Sunvepra) be reimbursed in Canada.
The Canadian Drug Expert Committee has recommended that asunaprevir be reimbursed for use in combination with daclatasvir dihydrochloride in patients with genotype 1b chronic hepatitis C infection and in combination with daclatasvir dihydrochloride and pegylated interferon plus ribavirin in patients with genotype 1 and 4 CHC, providing certain conditions are met.
